Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | ALB | P02768 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | TYMP | P19971 | 2/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.44 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.41 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12395247 | 0.90 | ALDH1A1 (0.71) | ALDH1A1LMNAALBMAPK1TYMP | |
| SCHEMBL21540015 | 0.87 | ALDH1A1 (0.73) | ALDH1A1LMNAALBMAPK1TYMP | |
| SCHEMBL14501117 | 0.84 | ALDH1A1 (0.64) | ALDH1A1LMNAALBMAPK1TYMP | |
| SCHEMBL14501040 | 0.84 | ALDH1A1 (0.61) | ALDH1A1LMNAALBMAPK1TYMP | |
| Didanosine SCHEMBL5021456 | 0.83 | ALDH1A1 (1.00) | ALDH1A1LMNAALBMAPK1TYMP | |
| Didanosine SCHEMBL16695883 | 0.83 | ALDH1A1 (1.00) | ALDH1A1LMNAALBMAPK1TYMP | |
| Didanosine SCHEMBL1674335 | 0.83 | ALDH1A1 (1.00) | ALDH1A1LMNAALBMAPK1TYMP | |
| Didanosine SCHEMBL16695885 | 0.83 | ALDH1A1 (1.00) | ALDH1A1LMNAALBMAPK1TYMP | |
| Didanosine SCHEMBL3363 | 0.83 | ALDH1A1 (1.00) | ALDH1A1LMNAALBMAPK1TYMP | |
| Didanosine SCHEMBL16695888 | 0.83 | ALDH1A1 (1.00) | ALDH1A1LMNAALBMAPK1TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140363482-A1 | Bioerodible Sustained Release Drug Delivery Systems | EyePoint Pharmaceuticals, Inc. | 2014-12-11 | — | — | US | disclosed |
| US-20130101656-A1 | IN SITU GELLING DRUG DELIVERY SYSTEM | CONTROL DELIVERY SYSTEMS, INC. | 2013-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140363482-A1 | Bioerodible Sustained Release Drug Delivery Systems | ABCB11, ABCB1, PGF | ALDH1A1 574/4885LMNA 4157/4885ALB 216/4885 |
| US-20130101656-A1 | IN SITU GELLING DRUG DELIVERY SYSTEM | ABCB11, MMP1, IDE | ALDH1A1 1254/4885LMNA 2989/4885ALB 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.